David F. Stojdl

9.9k total citations · 4 hit papers
59 papers, 7.7k citations indexed

About

David F. Stojdl is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, David F. Stojdl has authored 59 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 31 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in David F. Stojdl's work include Virus-based gene therapy research (44 papers), CAR-T cell therapy research (17 papers) and Viral Infectious Diseases and Gene Expression in Insects (10 papers). David F. Stojdl is often cited by papers focused on Virus-based gene therapy research (44 papers), CAR-T cell therapy research (17 papers) and Viral Infectious Diseases and Gene Expression in Insects (10 papers). David F. Stojdl collaborates with scholars based in Canada, United States and France. David F. Stojdl's co-authors include John C. Bell, Brian D. Lichty, Ricardo Marius, Harold Atkins, Jeffrey M. Leiden, Brian Popko, Yuhong Zhang, Marcella A. Calfon, Heather P. Harding and David Ron and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David F. Stojdl

59 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress

2003 2.6k citations David F. Stojdl, John C. Bell et al. profile →
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

2003 674 citations David F. Stojdl, Brian D. Lichty et al. Cancer Cell profile →
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

2000 663 citations David F. Stojdl, Brian D. Lichty et al. profile →
Going viral with cancer immunotherapy

2014 481 citations Brian D. Lichty, Caroline J. Breitbach et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David F. Stojdl Canada	31	3.7k	3.4k	2.2k	1.7k	1.6k	59	7.7k
Makoto Miyagishi Japan	45	7.2k 1.9×	1.3k 0.4×	1.6k 0.7×	928 0.5×	1.7k 1.0×	131	12.9k
Lindsey Moffat United Kingdom	8	4.9k 1.3×	2.2k 0.7×	1.0k 0.5×	440 0.3×	852 0.5×	10	7.7k
Carl A. Pinkert United States	41	4.4k 1.2×	2.3k 0.7×	1.3k 0.6×	372 0.2×	1.5k 0.9×	115	8.1k
G. Chinnadurai United States	47	6.2k 1.7×	2.4k 0.7×	1.5k 0.7×	426 0.2×	932 0.6×	141	7.9k
Robert R. Friis Germany	40	3.4k 0.9×	1.6k 0.5×	992 0.4×	545 0.3×	924 0.6×	116	6.0k
Tommy Alain Canada	38	3.5k 0.9×	1.2k 0.3×	892 0.4×	295 0.2×	539 0.3×	97	5.5k
Serge Y. Fuchs United States	58	6.3k 1.7×	536 0.2×	3.3k 1.5×	1.4k 0.8×	1.2k 0.7×	154	9.9k
Rollie J. Clem United States	39	6.3k 1.7×	653 0.2×	807 0.4×	469 0.3×	878 0.5×	76	8.2k
Thomas J. Gonda Australia	46	5.4k 1.5×	1.2k 0.4×	3.0k 1.4×	599 0.4×	413 0.3×	125	9.2k
Arnim Pause Canada	47	8.2k 2.2×	724 0.2×	885 0.4×	823 0.5×	1.2k 0.7×	79	10.6k

Countries citing papers authored by David F. Stojdl

Since Specialization

Citations

This map shows the geographic impact of David F. Stojdl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. Stojdl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. Stojdl more than expected).

Fields of papers citing papers by David F. Stojdl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. Stojdl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. Stojdl. The network helps show where David F. Stojdl may publish in the future.

Co-authorship network of co-authors of David F. Stojdl

This figure shows the co-authorship network connecting the top 25 collaborators of David F. Stojdl. A scholar is included among the top collaborators of David F. Stojdl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David F. Stojdl. David F. Stojdl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roy, Dominic G., Monique Marguerie, S. Khan, et al.. (2021). Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nature Communications. 12(1). 2626–2626. 51 indexed citations

Bourgeois‐Daigneault, Marie‐Claude, Dominic G. Roy, Amelia S. Aitken, et al.. (2018). Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine. 10(422). 233 indexed citations

Pol, Jonathan, Matthew J. Atherton, Byram W. Bridle, et al.. (2018). Development and applications of oncolytic Maraba virus vaccines. PubMed. Volume 7. 117–128. 38 indexed citations

Alkayyal, Almohanad A., Lee‐Hwa Tai, Michael A. Kennedy, et al.. (2017). NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunology Research. 5(3). 211–221. 59 indexed citations

Atherton, Matthew J., Kyle B. Stephenson, Jonathan Pol, et al.. (2017). Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer Immunology Research. 5(10). 847–859. 32 indexed citations

Muik, Alexander, Lawton J. Stubbert, Janine Kimpel, et al.. (2014). Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency. Cancer Research. 74(13). 3567–3578. 108 indexed citations

Mahoney, Douglas J., et al.. (2014). Virus Therapy for Cancer. Scientific American. 311(5). 54–59. 11 indexed citations

Lichty, Brian D., Caroline J. Breitbach, David F. Stojdl, & John C. Bell. (2014). Going viral with cancer immunotherapy. Nature reviews. Cancer. 14(8). 559–567. 481 indexed citations breakdown →

Zhang, Jiqing, Lee‐Hwa Tai, Carolina S. Ilkow, et al.. (2014). Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. Molecular Therapy. 22(7). 1320–1332. 54 indexed citations

10.

Bœuf, Fabrice Le, Cory Batenchuk, Markus Vähä‐Koskela, et al.. (2013). Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications. 4(1). 1974–1974. 35 indexed citations

11.

Yebdri, Fethia Ben, Julien van Grevenynghe, Vera A. Tang, et al.. (2013). Triptolide-Mediated Inhibition of Interferon Signaling Enhances Vesicular Stomatitis Virus-Based Oncolysis. Molecular Therapy. 21(11). 2043–2053. 23 indexed citations

12.

Pol, Jonathan, Liang Zhang, Byram W. Bridle, et al.. (2013). Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy. 22(2). 420–429. 128 indexed citations

13.

Mahoney, Douglas J. & David F. Stojdl. (2012). Functional genomic screening to enhance oncolytic virotherapy. British Journal of Cancer. 108(2). 245–249. 4 indexed citations

14.

Mahoney, Douglas J. & David F. Stojdl. (2012). Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses. Clinical Cancer Research. 19(4). 758–763. 9 indexed citations

15.

Cheung, Herman H., Shawn T. Beug, Eric C. LaCasse, et al.. (2011). SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. Cell Death and Disease. 2(4). e146–e146. 24 indexed citations

16.

Mahoney, Douglas J., Charles Lefebvre, J Brun, et al.. (2011). Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death. Cancer Cell. 20(4). 443–456. 77 indexed citations

17.

Mahoney, Douglas J. & David F. Stojdl. (2010). A call to arms: Using RNAi screening to improve oncolytic viral therapy. Cytokine & Growth Factor Reviews. 21(2-3). 161–167. 4 indexed citations

18.

Stojdl, David F., Brian D. Lichty, Benjamin R. tenOever, et al.. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4(4). 263–275. 674 indexed citations breakdown →

19.

Desforges, Marc, David F. Stojdl, Geneviève Despars, et al.. (2001). Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Research. 76(1). 87–102. 32 indexed citations

20.

Duncan, Peter I., David F. Stojdl, Ricardo Marius, K.H. Scheit, & John C. Bell. (1998). The Clk2 and Clk3 Dual-Specificity Protein Kinases Regulate the Intranuclear Distribution of SR Proteins and Influence Pre-mRNA Splicing. Experimental Cell Research. 241(2). 300–308. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact